Cargando…
Serum IL-33 level is a predictor of progression-free survival after chemotherapy
This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemothe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471039/ https://www.ncbi.nlm.nih.gov/pubmed/28402273 http://dx.doi.org/10.18632/oncotarget.16627 |
_version_ | 1783243875479977984 |
---|---|
author | Hu, Wenwei Wu, Chen Li, Xiaodong Zheng, Zhuojun Xie, Quanqin Deng, Xu Jiang, Jingting Wu, Changping |
author_facet | Hu, Wenwei Wu, Chen Li, Xiaodong Zheng, Zhuojun Xie, Quanqin Deng, Xu Jiang, Jingting Wu, Changping |
author_sort | Hu, Wenwei |
collection | PubMed |
description | This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemotherapy patients and healthy subjects, respectively. sIL-33 levels were 131.9 (95% CI 105.9-184.9) pg/mL, 95.1 (95% CI 70.8-140.2) pg/mL and 95.7 (95% CI 73.3-114.3) pg/mL in pre-chemotherapy patients, post-chemotherapy patients and controls, respectively. The sIL-33 level in pre-chemotherapy patients was significantly higher than that in both post-chemotherapy patients and controls (P < 0.001 and P < 0.001, respectively). There was no statistically significant difference between the sIL-33 levels in post-chemotherapy patients and controls (P > 0.05). PFS in patients with the decline extent > 30.1% (median PFS not reached) was statistically significant longer than that (median PFS 7 months, 95% CI 1.569 - 12.431) in patients with the decline extent ≤ 30.1% (P = 0.003). The decline extent of sIL-33 level (> 30.1%) was associated with longer PFS (P = 0.006). Distant metastasis was associated with the decline extent of sIL-33 level (P = 0.034). The decline extent of sIL-33 after chemoresistance could be regarded as a predictor of the PFS of GC patients. |
format | Online Article Text |
id | pubmed-5471039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54710392017-06-27 Serum IL-33 level is a predictor of progression-free survival after chemotherapy Hu, Wenwei Wu, Chen Li, Xiaodong Zheng, Zhuojun Xie, Quanqin Deng, Xu Jiang, Jingting Wu, Changping Oncotarget Research Paper This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemotherapy patients and healthy subjects, respectively. sIL-33 levels were 131.9 (95% CI 105.9-184.9) pg/mL, 95.1 (95% CI 70.8-140.2) pg/mL and 95.7 (95% CI 73.3-114.3) pg/mL in pre-chemotherapy patients, post-chemotherapy patients and controls, respectively. The sIL-33 level in pre-chemotherapy patients was significantly higher than that in both post-chemotherapy patients and controls (P < 0.001 and P < 0.001, respectively). There was no statistically significant difference between the sIL-33 levels in post-chemotherapy patients and controls (P > 0.05). PFS in patients with the decline extent > 30.1% (median PFS not reached) was statistically significant longer than that (median PFS 7 months, 95% CI 1.569 - 12.431) in patients with the decline extent ≤ 30.1% (P = 0.003). The decline extent of sIL-33 level (> 30.1%) was associated with longer PFS (P = 0.006). Distant metastasis was associated with the decline extent of sIL-33 level (P = 0.034). The decline extent of sIL-33 after chemoresistance could be regarded as a predictor of the PFS of GC patients. Impact Journals LLC 2017-03-28 /pmc/articles/PMC5471039/ /pubmed/28402273 http://dx.doi.org/10.18632/oncotarget.16627 Text en Copyright: © 2017 Hu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Hu, Wenwei Wu, Chen Li, Xiaodong Zheng, Zhuojun Xie, Quanqin Deng, Xu Jiang, Jingting Wu, Changping Serum IL-33 level is a predictor of progression-free survival after chemotherapy |
title | Serum IL-33 level is a predictor of progression-free survival after chemotherapy |
title_full | Serum IL-33 level is a predictor of progression-free survival after chemotherapy |
title_fullStr | Serum IL-33 level is a predictor of progression-free survival after chemotherapy |
title_full_unstemmed | Serum IL-33 level is a predictor of progression-free survival after chemotherapy |
title_short | Serum IL-33 level is a predictor of progression-free survival after chemotherapy |
title_sort | serum il-33 level is a predictor of progression-free survival after chemotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471039/ https://www.ncbi.nlm.nih.gov/pubmed/28402273 http://dx.doi.org/10.18632/oncotarget.16627 |
work_keys_str_mv | AT huwenwei serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT wuchen serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT lixiaodong serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT zhengzhuojun serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT xiequanqin serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT dengxu serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT jiangjingting serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy AT wuchangping serumil33levelisapredictorofprogressionfreesurvivalafterchemotherapy |